[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Osijek University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":262},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,74,102,132,163,201,232],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100623196","effect-of-apneic-oxygenation-of-the-non-ventilated-lung-during-lung-cancer-surgery-100623196",false,"NCT07393490","Effect of Apneic Oxygenation of the Non-ventilated Lung During Lung Cancer Surgery.","The Effect of Apneic Oxygenation of the Non-ventilated Lung on the Expression of Hypoxia-inducible Factor-1 Alpha (HIF-1α) and Interleukin-6 (IL-6) in Lung Tissue During Lung Cancer Surgery.","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Patients scheduled to undergo surgical resection of a single lung segment for lung cancer\n* Written informed consent provided\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Chronic corticosteroid therapy and\u002For other immunomodulatory treatments\n* Severe pulmonary diseases, including:\n\nChronic obstructive pulmonary disease classified as GOLD stage 3-4 (Global Initiative for Chronic Obstructive Lung Disease).\n\nSevere asthma according to GINA classification (Global Initiative for Asthma), step 4.\n\nSevere interstitial lung disease defined by: Forced vital capacity (FVC) \\\u003C 50% predicted, diffusing capacity of the lung for carbon monoxide (DLCO) \\\u003C 40% predicted, presence of extensive pulmonary fibrosis on computed tomography (CT)\n\n* Surgical procedure expected to last less than 2 hours\n* Intraoperative hemodynamic instability, defined as: Mean arterial pressure \\\u003C 60 mmHg for more than 30 minutes despite adequate volume resuscitation, requirement for high-dose vasopressor support (norepinephrine \\> 0.2 µg\u002Fkg\u002Fmin)\n* New-onset intraoperative cardiac arrhythmias\n* Significant intraoperative blood loss, defined as the need for transfusion of more than two units of packed red blood cells\n* Intraoperative ventilatory instability, defined as: Severe hypoxemia (PaO₂ \\\u003C 60 mmHg or SpO₂ \\\u003C 85% with FiO₂ 1.0), hypercapnia (PaCO₂ \\> 70 mmHg with pH \\\u003C 7.2), inability to achieve adequate ventilation.","ALL","18 Years",{"count":19,"type":20},56,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study investigates the effect of apneic oxygenation of the non-ventilated lung on local and systemic inflammatory response during lung cancer surgery.\n\nPatients undergoing surgical resection of lung cancer often require one-lung ventilation during anaesthesia. This results in alveolar hypoxia accompanied by upregulated expression of inflammatory markers. Apneic oxygenation of the non-ventiladed lung may influence inflammatory processes and oxygenation during surgery. The aim of this study is to evaluate whether apneic oxygenation affects inflammatory markers in lung tissue and postoperative recovery in patients undergoing lung cancer surgery. The study is conducted at a single center and includes adult patients scheduled for elective lung cancer surgery. Data will be collected durig the perioperative period. The results of this study may contribute to improved anaesthetic management and patient outcomes during thoracic surgery.",[26],"Lung Cancer (Diagnosis)",[28,29,30,31,32,33],"One-lung ventilation","Apneic oxygenation","Inflammatory response","Hif 1 alpha","Interleukin 6","Thoracic anaesthesia","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-26","ACTUAL",{"date":40,"type":38},"2025-01-02",{"date":42,"type":20},"2026-09",{"name":44,"class":45},"Osijek University Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":52,"conditions":57,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100629522","ultrasound-nutritional-status-and-outcomes-in-surgical-icu-100629522","NCT07475767","Ultrasound, Nutritional Status, and Outcomes in Surgical ICU","Ultrasound Indicators of Nutritional Status and Treatment Outcomes in Surgical Patients in the Intensive Care Unit","Inclusion Criteria:\n\n* postoperative intensive care\n\nExclusion Criteria:\n\n* surgery of the right leg\n* paraplegia, tetraplegia\n* refusal of the patient\u002Fguardian to participate in the research (informed consent not signed)",{"count":55,"type":20},50,"OBSERVATIONAL",[58,59,60],"Nutritional Status","Muscle Thickness of the Quadriceps Femoris","Frailty",[58,62,63,64,65],"Risk Assessment","Ultrasonography","Intensive Care Units","Postoperative Care","2026-05-27",{"date":68,"type":38},"2026-05-29",{"date":70,"type":38},"2026-02-01",{"date":72,"type":20},"2026-07",{"name":44,"class":45},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100632927","biomarkers-in-diabetic-retinopathy-treated-with-faricimab-vs-biosimilar-ranibizumab-100632927","NCT07520045","Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab","A Comparative Analysis of OCT and OCT Angiography Biomarkers and Systemic Laboratory Parameters in Patients With Diabetic Retinopathy Undergoing Treatment With Faricimab or Biosimilar Ranibizumab Following Three Loading Doses","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Diabetic retinopathy with or without central macular edema\n* Indication for intravitreal anti-VEGF therapy according to current clinical guidelines\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Intravitreal anti-VEGF or corticosteroid treatment in the study eye within 5 months prior to enrollment\n* Any intraocular surgery (including cataract surgery) 3 months prior intraocular surgery to enrollment\n* Retinal laser photocoagulation in the study eye within 3 months prior to enrollment\n* Presence of other ocular, retinal or macular diseases that may affect OCT\u002FOCTA findings or visual acuity (e.g., age-related macular degeneration, retinal vascular occlusions)\n* Retinal detachment, preretinal fibrosis, vitreomacular traction\n* Significant media opacities (e.g., dense cataract, vitreous hemorrhage) precluding reliable OCT\u002FOCTA imaging\n* Uncontrolled glaucoma (intraocular pressure \\> 30 mmHg in study eye)\n* Active ocular inflammation\n* Suspected active ocular infection in either eye\n* Any febrile illness within 1 week prior to first injection\n* History or presence of any clinically significant disease, non-diabetic metabolic disorder, abnormal physical examination finding, or laboratory abnormality that, in the opinion of the investigator, may contraindicate treatment with faricimab or biosimilar ranibizumab, interfere with the interpretation of study results, or place the participant at increased risk of treatment-related complications.\n* Women who are pregnant, breastfeeding, or planning pregnancy within the next 100 weeks\n* Known hypersensitivity to faricimab or biosimilar ranibizumab or any of its excipients\n* Participation in another clinical trial that may affect study outcomes\n* Inability to comply with study procedures or follow-up",{"count":82,"type":20},100,[23],"The goal of this clinical trial is to see if treatment with faricimab or biosimilar ranibizumab leads to different early imaging changes in adults with diabetic retinopathy requiring anti-VEGF treatment and to identify OCT and OCTA biomarkers predictive of differential early treatment response between the two therapies. The main questions it aims to answer are:\n\nWhich OCT and OCT angiography biomarkers predict early treatment response? How do imaging biomarkers change after three loading doses of treatment? Are imaging biomarkers associated with systemic laboratory parameters? Researchers will compare faricimab to biosimilar ranibizumab to see if there are differences in imaging biomarkers and early treatment response.\n\nParticipants will:\n\n* be randomized in a 1:1 ratio using a computer-generated randomization sequence\n* undergo comprehensive ophthalmic examinations, including visual acuity and intraocular pressure measurement\n* undergo OCT and OCT angiography imaging at each visit\n* receive three intravitreal injections during the loading phase\n* attend follow-up visits from baseline to 4-5 weeks after the third injection\n* provide blood samples for systemic laboratory analysis",[86,87],"Diabetic Retinopathy (DR)","Diabetic Macular Edema (DME)",[89,90,91,92,93],"Diabetic Retinopathy","ranibizumab","faricimab","biomarkers","OCT","2026-04-02",{"date":96,"type":38},"2026-04-09",{"date":98,"type":38},"2026-03-12",{"date":100,"type":20},"2027-06-01",{"name":44,"class":45},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":46},"100627913","real-time-treatment-of-chronic-pain-using-digital-intelligence-100627913","NCT07454811","Real-time Treatment of Chronic Pain Using Digital Intelligence","Effectiveness of Digital Intelligence-Supported Real-Time Management in Adults With Chronic Pain: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Age 18-65 years Chronic low back pain significantly affecting disability and\u002For emotional distress\n\n  * Active use of Croatian language\n  * Signed informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>65\n\n  * Acute pain\n  * Previous participation in multidisciplinary program\n  * Pregnancy or cancer-related pain\n  * Psychotic disorders, moderate-severe cognitive impairment, urgent psychiatric conditions\n  * PTSD symptoms, extreme fatigue, low motivation, low literacy\n  * Allergic reactions to metal or silicone","65 Years",{"count":111,"type":20},80,[23],"This randomized controlled study will evaluate the effectiveness of real-time digital intelligence in the treatment of chronic pain. A total of 80 adult patients enrolled in a four-week multidisciplinary chronic pain programme will be randomly assigned to either standard treatment alone or standard treatment supported by a smartwatch and a mobile application for real-time monitoring of pain intensity, analgesic use, physical activity, and heart rate.\n\nBoth groups will complete validated questionnaires assessing pain intensity, disability, quality of life, sleep, anxiety, depression, and treatment satisfaction at baseline, two weeks, and four weeks. The intervention group will additionally record daily pain scores and medication use via a mobile application and wear a smartwatch for continuous activity and heart rate monitoring.\n\nThe study aims to determine whether real-time digital monitoring and physician availability improve clinical outcomes compared with standard multidisciplinary care alone.",[115,116,117],"Chronic Pain","Multidisciplinary Biopsychosocial Program","Quality of Life",[119,120,121,122],"digital intelligence","real-time pain treatment","chronic pain","pain management","NOT_YET_RECRUITING","2026-03-02",{"date":126,"type":38},"2026-03-06",{"date":128,"type":20},"2026-03-09",{"date":130,"type":20},"2028-03-09",{"name":44,"class":45},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":142,"studyType":56,"phases":4,"briefSummary":143,"conditions":144,"keywords":149,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":46},"100625464","perioperative-outcomes-after-neoadjuvant-therapy-in-colorectal-cancer-100625464","NCT07422974","Perioperative Outcomes After Neoadjuvant Therapy in Colorectal Cancer","The Impact of Neoadjuvant Therapy on Perioperative Complications and Treatment Outcomes in Patients Undergoing Colorectal Cancer Resection","Neocolon","Inclusion Criteria:\n\n* Adults aged ≥18 years with histologically confirmed colorectal cancer\n* Planned surgical treatment for colorectal cancer (either laparoscopic LPSC or open laparotomy)\n* Ability to understand the study protocol and provide written informed consent.\n* Both sexes\n* ASA classification II or III\n* Patients who received neoadjuvant therapy is investigational group and patients who did not receive neoadjuvant therapy is control group\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Patients who are not conscious, not oriented, or unable to provide informed consent\n* Patients unable to understand the study protocol\n* Emergency surgical cases\n* Patients on chronic corticosteroid therapy",{"count":141,"type":20},68,"2 Months","This prospective study investigates the effects of neoadjuvant therapy on endothelial function, microvascular tissue density, and tissue fibrosis in patients with colorectal cancer and their association with perioperative complications. The primary objective is to assess differences in microvascular tissue density between patients who received neoadjuvant therapy and those who did not, biomarkers, and demographic factors between patients who received neoadjuvant therapy and those who underwent surgery as initial treatment, and to compare clinical outcomes. The study will include 34 patients treated with neoadjuvant therapy and 34 patients for whom surgery is the first-line treatment. Patients will be followed until discharge from the hospital, and complications after discharge will be monitored through medical records one month after surgery.",[145,146,147,148],"Colorectal Carcinoma (CRC)","Complications","Neoadjuvant Therapy","Endothelial Dysfunction",[150,147,151,152,153,154],"Colorectal Carcinoma","Microvascular Density","Treatment Outcome","Wound Healing","Critical care","2026-02-13",{"date":157,"type":38},"2026-02-20",{"date":159,"type":38},"2026-01-09",{"date":161,"type":20},"2027-05-01",{"name":44,"class":45},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":173,"conditions":174,"keywords":186,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":46},"100605647","association-of-pocd-with-circulating-biomarkers-in-patients-undergoing-tur-of-bladder-tumor-100605647","NCT07165236","Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor","Association of Perioperative Cognitive Dysfunction With Circulating Biomarkers of Neurological Damage in Patients Underging Transurethral Resection of Bladder Tumor","Inclusion Criteria:\n\n* adult patients from 18-80 years,\n* elective operations of tumor bladder cancer (TUR),\n* patients can communicate,\n* patients who can sign the information consent and questionnaires\n\nExclusion Criteria:\n\n* patients under the age of 18,\n* patients above 80 years,\n* patients who are unable to communicate\n* patients who do not understand informed consent for the research,\n* patients who are unable to write\n* emergency surgery,\n* patients with proven hypersensitivity to some of the drugs used in the study\n* patients in a state of shock, septic, or hemorrhagic patients with neurodevelopmental disorders","80 Years",{"count":172,"type":20},42,"Bladder tumor is one of the most widespread tumors in the world, with increasing prevalence at the global level. One of the procedures in patients with bladder tumors is transurethral resection of the bladder (TURM) most often performed endoscopically under general anesthesia. This patient population has certain characteristics in common. One of them is exposure to common risk factors for the formation of bladder tumors, such as aniline dyes and solvents. These substances are associated with the onset of neurodegeneration and oxidative stress. Smoking is another factor that affects the formation of bladder tumor. A significant part of patients with bladder tumor are an elderly population, which is repeatedly exposed to surgical procedures, with numerous comorbidities, with a high risk of postoperative complications and the development of perioperative cognitive deficits, which can further complicate the postoperative course and further treatment. In the group of patients with a bladder tumor who will undergo TURM, no evaluation of risk factors related to perioperative cognitive deficit was performed, nor was there an examination of the perioperative cognitive deficit itself. In them, the identification of factors for postoperative cognitive disorder is essential. The concept of clinical frailty is becoming more important and relevant when providing healthcare services to patients. The use of the clinical frailty scale as a tool in clinical practice provides information on the adequate direction of care for patients. Decrease in muscle strength can lead to limitations in the functioning of a certain individuals. In recent years muscle strength has come to be a very important component of health, regardless of a person's age and clinical condition.The hand grip test is a test used to measure the maximum isometric strength of the hand and forearm muscles. The MMSE test and MoCA are the most frequently used methods in the detection of cognitive impairment in clinical and research fields. In addition to laboratory indicators of organic function, circulating indicators of neuroinflammation, like S100B and neuron-specific enolase, will be correlated with the patient's cognitive status.So far, no research has been conducted on the dynamics of indicators of organic function, circulating indicators of neuroinflammation, perioperative cognitive changes and clinical fraility in patients undergoing bladder tumor operation.",[175,176,177,178,179,180,181,182,183,184,185],"Cognitive Decline","Urinary Bladder Cancer","Frail","Biomarker","General Anesthesia","Hand Grip Strength","Cognitive Testing","Comorbidities","Demographic Data","Socio-economic Status","Perioperative Complications",[187,188,189,190,191,192],"general anesthesia","postoperative cognitive complications","urinary bladder neoplasm","perioperative period","frail older adult","S100b","2025-09-02",{"date":195,"type":38},"2025-09-10",{"date":197,"type":38},"2024-11-28",{"date":199,"type":20},"2029-10-01",{"name":44,"class":45},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":212,"conditions":213,"keywords":218,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":46},"100481492","the-effect-of-upper-blepharoplasty-on-vision-quality-in-the-early-postoperative-period-100481492","NCT05549713","The Effect of Upper Blepharoplasty on Vision Quality in the Early Postoperative Period","The Effect of Upper Blepharoplasty on Anatomical and Functional Aspects of Vision in the Early Postoperative Period","Inclusion Criteria:\n\n* Patients with functional dermatochalasis on the upper eyelid with subjective difficulties due to obstructing the upper part of visual field: swelling of the eyelids in the morning with difficulties in opening the eyes, use of the frontal musculature to be able to have at least a partial width of the field of vision in the upper part that is adequate for daily functioning, and headaches.\n\nExclusion Criteria:\n\n* History of corneal refractive surgery, pterygium, glaucoma, nuclear sclerosis \\> 4th degree, severe dry eye, age-related macular degeneration, neuro-ophthalmological diseases, use of hormone therapy, diabetic retinopathy or condition after panretinal photocoagulation. Corneal pathologies such as keratoconus and gross eyelid malposition conditions such as entropion, ectropion and marked laxity of the eyelids are also grounds for exclusion from the study.","45 Years","90 Years",{"count":211,"type":20},40,"Contrast sensitivity (CS) and tear film (TF) changes are noted in late postoperative period after upper blepharoplasty (UB), while the same was rarely investigated in the early postoperative period. The reason for aforementioned improvement of vision quality is unclear. Suggested explanations include changes in higher-order aberrations, elimination of the overlay effect created by excess skin on the upper eyelids and\u002For eyelashes directed toward the eyelid, or changes in corneal topography (CT) and keratometry.\n\nFurthermore, there is no consensus on the best technique for UB. Due not only to different surgical techniques, but also to different methods of measuring the tear film quality, it is very difficult to quantify the aforementioned studies.\n\nWhile changes in tear volume parameters and changes in tear film (TF) rupture have been investigated in detail, changes in the lipid layer have rarely been investigated.\n\nAccording to previous studies, there are different findings about changes in CT after UB.\n\nThe aim of the research is to determine whether there are anatomical (CT) and functional (TF and CS) changes in subjects with functional dermatochalasis before the procedure and in a month-long postoperative period.\n\nThe research is conducted on examinees diagnosed by clinical examination with functional dermatochalasis with the exclusion of examinees with ocular or systemic conditions affecting TF, best corrected visual acuity or CT.\n\nDetailed medical history and ophthalmologic examination will be performed with grading of the external appearance of the upper eyelids. All diseases and conditions that can lead to changes in CS, TF or corneal defects will be noted. Preoperatively all subjects will have CS recorded in photopic conditions, TF analysis and CT (Keratograph 5M, OCULUS Optikgeraete GmbH, Wetzlar, Germany). UB will be performed in the operating room at the UED. At first (seven days postoperatively) and second (one month postoperative) check-up a CS check will be performed at the UED and TF analysis and CT at Lens LTD.",[214,215,216,217],"Excess Skin of Both Eyelids","Contrast Sensitivity","Tear Film Insufficiency of Both Eyes","Corneal Topography",[219,220,221,222,223],"Corneal topography","Contrast sensitivity","Eyelid disease","Meibomian gland dysfunction","Blepharoplasty","2024-12-30",{"date":226,"type":38},"2024-12-31",{"date":228,"type":38},"2022-09-08",{"date":230,"type":20},"2026-01-01",{"name":44,"class":45},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":209,"enrollmentInfo":240,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":242,"conditions":243,"keywords":249,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":46},"100453219","retrospective-analysis-of-chest-x-ray-severity-scoring-system-of-covid-19-pneumonia-100453219","NCT05181696","Retrospective Analysis of Chest X-ray Severity Scoring System of COVID-19 Pneumonia","Radiographic Severity Scoring System and Clinical and Laboratory Evolution of COVID-19 Pneumonia","RANCH-COVID","Inclusion Criteria:\n\n* Pneumonia caused by SARS-CoV-2 virus\n* Admission to the ICU COVID-19 unit\n\nExclusion Criteria:\n\n\\- Patients with lung tumors or history of lung resection",{"count":241,"type":20},200,"The research will be retrospective, and will include all patients who were admitted during 2020 and 2021 in the COVID-19 ICU of University Hospital Center Osijek due to pneumonia caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The association of chest x-ray infiltrate evolution with changes in laboratory inflammatory parameters and respiratory function parameters will be examined.",[244,245,246,247,248],"COVID-19 Pneumonia","Sepsis","SARS-CoV-2 Acute Respiratory Disease","Pneumonia","Multiorgan Failure",[250,251,245,248,252,253],"COVID-19","Acute respiratory distress syndrome (ARDS)","Chest X-ray","Inflammation","2024-09-04",{"date":256,"type":38},"2024-09-19",{"date":258,"type":38},"2020-01-01",{"date":260,"type":20},"2025-05",{"name":44,"class":45},""]